2010年,一项双盲RCT研究,比较5-ASA4.0 g/d与AZA预防CD术后复发的疗效,结果发现 5-ASA预防术后复发(CDAI≥200分、比治疗前基线上升60分,及治疗无效)疗效比例和AZA相比无明显统计学差异(22%与11%,P=0.19),但是在临床复发方面AZA优于5-ASA ( 0%v s 11% ,P=0.031);且患者对5-ASA具有良好耐受性。不过,...
7. A. Hart, et al. A national, retrospective, observational study on the use of 5-aminosalicylates (5-ASA) in Crohn’s disease (CD).2019 ECCO: P569. Document Number: ETI-CN-000965 有效期至2020年11月20日 声明 本视频/资讯/文...
因此,有必要在大规模且长期随访的队列中比较接受抗肿瘤坏死因子药物治疗的IBD患者继续或停用5-ASA药物后的临床结局。 该项基于人群的全国性回顾性队列研究纳入韩国2008年至2019年接受至少90天抗肿瘤坏死因子药物治疗的IBD患者,并定义首次接...
Nephrotoxicity was seen with all aminosalicylates including 1 patient treated with topical therapy only. Nephrotoxicity occurred at a median age of 36.5 yrs (range 15.4鈥 88.4 yrs). Two patients had a confirmed family history of 5-ASA-induced nephrotoxicity. 78% were detected by ...
mesalamine (5-aminosalicylic acid, 5-ASA, mesalazine, mesalazine (UK)) Apriso, Asacol, Asacol HD, Canasa, Ipocol (UK), Lialda, Mesasal (CA), Mesren (UK), Mezavant (CA), Novo-5-ASA-Ect (CA), Pentasa, Rowasa, Salofalk (CA) (UK) Pharmacologic class: 5-amino-2-hydroxybenzoic acid...
For decades, variability in clinical efficacy of the widely used inflammatory bowel disease (IBD) drug 5-aminosalicylic acid (5-ASA) has been attributed, in part, to its acetylation and inactivation by gut microbes. Identification of the responsible microbes and enzyme(s), however, has proved el...
Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 617-29.Ford AC, Kane SV, Khan KJ, Achkar JP et al. Efficacy of 5- aminosalicylates in Crohn's disease: systematic review and meta- analysis. Am J Gastroenterol 2011; ...
Cancer chemoprevention has obvious attractions, particularly using agents such as 5-aminosalicylates (5-ASAs), which may already being used to maintain remission. Besides the anti-inflammatory effects of 5-ASAs, there are several other plausible mechanisms by which they might have chemopreventive ...
Aminosalicylates (5-ASAs) are foundational therapies for patients with mild-moderate active ulcerative colitis (UC) and to maintain remissions. A variety of oral and topical formulations have been evaluated in both active and quiescent disease in both extensive and distal UC. This review summarizes ...
Synonyms: 5-Aminosalicylic acid, 98.5%, IKK inhibitor;2-HYDROXY-5-AMINOBENZOIC ACID;3-Carboxy-4-hydroxyaniline;5-AMINO-2-HYDROXYBENZOIC ACID;5-AMINOSALICYLIC ACID;5-ASA;5-AS;rowasa CAS: 89-57-6 MF: C7H7NO3 MW: 153.14 EINECS: 201-919-1 Product Categories: API;CITANEST;Pharmaceuticals;Carb...